6
Tetrahedron
ACCEPTED MANUSCRIPT
(3H, 2s, SO2C6H4CH3), 4.08 (4e), 4.13 (3e) (3H, 2s, COOCH3),
125.5, 126.0, 126.1, 127.5, 127.6, 127.9, 128.1, 128.9, 129.0,
7.38–7.44 (2H, m, Harom.), 8.02–8.08 (2H, m, Harom.), 8.76 (4e),
9.36 (3e) (1H, 2s, C5–H); 13C NMR (100 MHz, CDCl3): δ 21.9,
22.0, 53.3, 53.4, 124.9, 125.9, 129.0, 129.2, 130.5, 130.7, 132.0,
132.3, 135.7, 138.3, 139.2, 146.7, 147.7, 148.1, 149.6, 151.2,
160.9, 161.4; MS m/z EI (70 eV), (I, %): 365 (M+, 7), 155 (30),
91 (100), 65 (30); Anal. Calcd for C13H11N5O4S2 (365.39): C,
42.73; H, 3.03; N, 19.17; S, 17.55. Found: C, 43.03; H, 2.86; N,
18.95; S, 17.66.
130.4, 131.6, 131.7, 131.9, 133.8, 134.1, 134.4, 137.1, 137.5,
140.2, 140.3, 147.8, 148.3, 167.4, 167.6, 169.0, 169.2; MS m/z EI
(70 eV), (I, %): 381 (M+, 10), 169 (13), 105 (100), 77 (40); Anal.
Calcd for C18H15N5O3S (381.41): C, 56.68; H, 3.96; N, 18.36; S,
8.41. Found: C, 56.91; H, 4.21; N, 18.23; S, 8.59.
4i: Colourless crystals, yield 26%, 0.23 g, mp 176–178 °C
(from EtOAc, double recrystallization); H NMR (400 MHz,
CDCl3):
1
δ 2.40 (3H, s, SO2C6H3(CH3)2), 2.69, (3H, s,
4.4.5. Methyl 5-(1-(4-fluorophenylsulfonyl)-1H-1,2,3-triazol-4-
yl)-1,2,3-thiadiazole-4-carboxylate (3f) and methyl 5-(2-(4-
fluorophenylsulfonyl)-2H-1,2,3-triazol-4-yl)-1,2,3-thiadiazole-4-
carboxylate (4f).
SO2C6H3(CH3)2), 7.17 (1H, s, Harom.), 7.26 (1H, d, J 8.0 Hz,
Harom.), 7.49–7.55 (3H, m, Harom.), 8.15 (2H, d, J 8.0 Hz, Harom.),
8.20 (1H, d, J 8.0 Hz, Harom.), 8.43 (1H, s, C5–H); 13C NMR (100
MHz, CDCl3): δ 20.6, 21.6, 126.0, 127.6, 127.9, 128.9, 130.5,
131.6, 131.9, 134.1, 137.1, 137.5, 140.4, 147.7, 167.5, 169.2;
Anal. Calcd for C18H15N5O3S (381.41): C, 56.68; H, 3.96; N,
18.36; S, 8.41. Found: C, 56.59; H, 3.87; N, 18.30; S, 8.47.
Colourless crystals, yield 83%, 0.081 g, mp 129–132 °C; 3f/4f
ratio is 63:37; 1H NMR (400 MHz, CDCl3): δ 4.07 (4f), 4.12 (3f)
(3H, 2s, COOCH3), 7.29–7.35 (2H, m, Harom.), 8.15–8.23 (2H, m,
Harom.), 8.77 (4f), 9.36 (3f) (1H, 2s, C5–H); 13C NMR (100 MHz,
CDCl3): 53.3, 53.4, 117.5, 117.7, 125.0, 131.0, 131.3, 132.2,
132.3, 135.8, 146.4, 148.4, 149.3, 150.9, 160.8, 161.4, 167.2,
167.3; MS m/z EI (70 eV), (I, %): 369 (M+, 10), 277 (20), 159
(57), 95 (100); Anal. Calcd for C12H8FN5O4S2 (369.35): C, 39.02;
H, 2.18; N, 18.96; S, 17.36. Found: C, 39.14; H, 2.24; N, 18.90;
S, 17.58.
4.4.9. 5-(1-(Methylsulfonyl)-1H-1,2,3-triazol-4-yl)-3-
phenylisoxazole-4-carbonitrile (3j) and 5-(2-(methylsulfonyl)-
2H-1,2,3-triazol-4-yl)-3-phenylisoxazole-4-carbonitrile (4j).
Colourless crystals, yield 40%, 0.16 g, mp 150–153 °C (from
EtOAc); 3j/4j ratio is 90:10; 1H NMR (400 MHz, CDCl3): δ 3.63
(4j), 3.69 (3j) (3H, 2s, SO2CH3), 7.54–7.62 (3H, m, Harom.), 8.01–
8.04 (2H, m, Harom.), 8.53 (4j), 8.81 (3j) (1H, 2s, C5-H); 13C
NMR (100 MHz, CDCl3): 41.8, 42.9, 110.8, 111.1, 123.7, 125.4,
125.6, 127.5, 129.4, 129.5, 131.8, 131.9, 133.8, 134.2, 134.9,
136.2, 137.6, 146.3, 161.8, 162.0, 166.3, 166.6; MS m/z EI (70
eV), (I, %): 315 (M+, 8), 236 (32), 169 (20), 79 (Ms, 100); Anal.
Calcd for C13H9N5O3S (315.31): C, 49.52; H, 2.88; N, 22.21; S,
10.17. Found: C, 49.19; H, 3.17; N, 22.45; S, 9.98.
4.4.6. 5-(1-(Methylsulfonyl)-1H-1,2,3-triazol-4-yl)-3-phenyl-
1,2,4-oxadiazole (3g) and 5-(2-(methylsulfonyl)-2H-1,2,3-triazol-
4-yl)-3-phenyl-1,2,4-oxadiazole (4g).
Colourless crystals, yield 63%, 0.40 g, mp 122–127 °C; 3g/4g
ratio is 50:50; 1H NMR (400 MHz, CDCl3): δ 3.60 (4g), 3.67 (3g)
(3H, 2s, SO2CH3), 7.50–7.59 (3H, m, Harom.), 8.17–8.20 (2H, m,
Harom.), 8.55 (4g), 8.86 (3g), (1H, 2s, C5–H); 13C NMR (100
MHz, CDCl3): δ 41.9, 42.9, 125.4, 125.9, 126.0, 127.7, 128.9,
129.0, 129.1, 131.5, 131.7, 131.8, 137.7, 137.9, 147.6, 149.3,
167.1, 167.2, 169.2, 169.3; MS m/z EI (70 eV), (I, %): 291 (M+,
10), 212 (21), 145 (47), 79 (Ms, 100); Anal. Calcd for
C11H9N5O3S (291.29): C, 45.36; H, 3.11; N, 24.04; S, 11.01.
Found: C, 45.13; H, 3.25; N, 24.11; S, 11.09.
4.4.10. 3-Phenyl-5-(1-tosyl-1H-1,2,3-triazol-4-yl)isoxazole-4-
carbonitrile (3k) and 3-phenyl-5-(2-tosyl-2H-1,2,3-triazol-4-
yl)isoxazole-4-carbonitrile (4k).
Colourless crystals, yield 95%, 0.25 g, mp 198-201 °C; 3k/4k
1
ratio is 55/45; H NMR (400 MHz, CDCl3): δ 2.46 (4k), 2.49
(3k) (3H, 2s, SO2C6H4CH3), 7.41–7.46 (2H, m, Harom.), 7.52–7.60
(3H, m, Harom.), 7.98–8.01 (2H, m, Harom.), 8.07–8.12 (2H, m,
Harom.), 8.40 (4k), 8.79 (3k) (1H, 2s, C5–H); 13C NMR (100 Mz,
CDCl3): δ 21.9, 22.0, 110.7, 111.1, 123.6, 125.5, 127.5, 125.7,
129.2, 129.3, 129.4, 129.5, 130.6, 130.8, 131.7, 131.8, 134.0,
136.1, 137.4, 147.9, 148.5, 161.7, 161.8, 166.3, 166.6; MS m/z EI
(70 eV), (I, %): 391 (M+, 9), 139 (100), 91 (93), 77 (29); Anal.
Calcd for C19H13N5O3S (391.40): C, 58.30; H, 3.35; N, 17.89; S,
8.19; Found: C, 58.59; H, 3.08; N, 17.76; S, 8.37.
4.4.7. 3-Phenyl-5-(1-tosyl-1H-1,2,3-triazol-4-yl)-1,2,4-
oxadiazole (3h) and 3-phenyl-5-(2-tosyl-2H-1,2,3-triazol-4-yl)-
1,2,4-oxadiazole (4h).
Colourless crystals, yield 85%, 0.29 g, mp 177–180 °C; 3h/4h
1
ratio is 50:50; H NMR (400 MHz, CDCl3): δ 2.45 (4g), 2.48
(3h) (3H, 2s, SO2C6H5CH3), 7.40–7.45 (2H, m, Harom.), 7.48–7.56
(3H, m, Harom.), 8.06–8.10 (2H, m, Harom.), 8.14–8.17 (2H, m,
Harom.), 8.43 (4h), 8.86 (3h) (1H, 2s, C5–H); 13C NMR (100
MHz, CDCl3): δ 21.8, 21.9, 125.4, 126.0, 126.1, 127.5, 127.6,
128.9, 129.0, 129.1, 129.3, 130.5, 130.8, 131.6, 131.7, 132.0,
132.1, 133.9, 137.5, 137.9, 147.8, 148.4, 167.4, 167.6, 169.0,
169.2; MS m/z EI (70 eV), (I, %): 367 (M+, 9), 155 (40), 145
(33), 91 (100); Anal. Calcd for C17H13N5O3S (367.38): C, 55.58;
H, 3.57; N, 19.06; S, 8.73. Found: C, 55.39; H, 3.89; N, 18.96; S,
8.64.
4.4.11. 5-(1-(2,4-Dimethylphenylsulfonyl)-1H-1,2,3-triazol-4-
yl)-3-phenylisoxazole-4-carbonitrile
(3l)
and
5-(2-(2,4-
dimethylphenylsulfonyl)-2H-1,2,3-triazol-4-yl)-3-
phenylisoxazole-4-carbonitrile (4l).
Colourless crystals, yield 91%, 0.124 g, mp 142–145 °C; 3l/4l
ratio is 59:41; 1H NMR (400 MHz, CDCl3): δ 2.40 (4l), 2.43 (3l)
(3H, 2s, SO2C6H3(CH3)2), 2.70 (3l), 2.75 (4l) (3H, 2s,
SO2C6H3(CH3)2), 7.19–7.29 (2H, m, Harom.), 7.53–7.60 (3H, m,
Harom.), 7.97–8.02 (2H, m, Harom.), 8.15–8.20 (1H, m, Harom.), 8.39
(4l), 8.81 (3l) (1H, 2s, C5–H); 13C NMR (100 Mz, CDCl3): δ
20.8, 20.9, 21.6, 21.7, 110.7, 111.1, 123.2, 123.6, 125.5, 125.7,
127.5, 127.9, 128.2, 129.3, 129.4, 130.3, 131.6, 131.7, 131.9,
133.9, 134.2, 134.4, 135.8, 137.1, 140.4, 140.7, 147.9, 148.4,
161.7, 161.8, 166.3, 166.7; MS m/z EI (70 eV), (I, %): 405 (M+,
11), 169 (30), 105 (100), 77 (66); Anal. Calcd for C20H15N5O3S
(405.43): C, 59.25; H, 3.73; N, 17.27; S, 7.91; Found: C, 59.55;
H, 3.45; N, 17.35; S, 8.17.
4.4.8. 5-(1-(2,4-Dimethylphenylsulfonyl)-1H-1,2,3-triazol-4-yl)-
3-phenyl-1,2,4-oxadiazole (3i) and 5-(2-(2,4-
dimethylphenylsulfonyl)-2H-1,2,3-triazol-4-yl)-3-phenyl-1,2,4-
oxadiazole (4i).
Colourless crystals, yield 80%, 0.71 g, mp 150–153 °C; 3i/4i
ratio is 12:88; 1H NMR (400 MHz, CDCl3): δ 2.40 (4i), 2.43 (3i)
(3H, 2s, SO2C6H3(CH3)2), 2.68 (3i), 2.69 (4i) (3H, 2s,
SO2C6H3(CH3)2), 7.17–7.29 (2H, m, Harom.), 7.49–7.56 (3H, m,
Harom.), 8.14–8.22 (3H, m, Harom.), 8.43 (4i), 8.88 (3i) (1H, 2s,
C5–H); 13C NMR (100 MHz, CDCl3): δ 20.6, 20.7, 21.6, 21.7,